Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation - PubMed (original) (raw)
Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson-Gilford progeria syndrome mutation
Shao H Yang et al. Biochim Biophys Acta. 2008 Jan-Feb.
Abstract
Hutchinson-Gilford progeria syndrome (HGPS) is a progeroid syndrome characterized by multiple aging-like disease phenotypes. We recently reported that a protein farnesyltransferase inhibitor (FTI) improved several disease phenotypes in mice with a HGPS mutation (Lmna(HG/+)). Here, we investigated the impact of an FTI on the survival of Lmna(HG/+) mice. The FTI significantly improved the survival of both male and female Lmna(HG/+) mice. Treatment with the FTI also improved body weight curves and reduced the number of spontaneous rib fractures. This study provides further evidence for a beneficial effect of an FTI in HGPS.
Figures
Fig. 1
Western blot analysis of liver extracts. FTI treatment of Lmna+/+ mice leads to the appearance of nonfarnesylated HDJ-2 (with an antibody against HDJ-2) in liver extracts. FTI treatment also leads to the appearance of nonfarnesylated prelamin A (as judged by a western blot with a prelamin A–specific antibody). However, the amount of prelamin A accumulation was small, as judged by a western blot with an antibody against lamin A/C (prelamin A is a faint shadow above a large lamin A band). The FTI did not reduce the levels of mature lamin A.
Fig. 2
Kaplan-Meier survival plots for _Lmna_HG/+ mice treated with an FTI or vehicle alone. Male _Lmna_HG/+ mice on vehicle (n = 8); male _Lmna_HG/+ mice on FTI (n = 10); female _Lmna_HG/+ mice on vehicle (n = 8); female _Lmna_HG/+ mice on FTI (n = 13).
Fig. 3
Disease phenotypes in _Lmna_HG/+ mice with FTI treatment. (a and b) Body weight curves for male (a) and female (b) _Lmna_HG/+ and littermate Lmna+/+ mice treated with an FTI or vehicle alone, beginning at four weeks of age. The body weight curves for FTI-treated _Lmna_HG/+ mice were significantly different than those of the vehicle-treated _Lmna_HG/+ mice, both in males and in females (P < 0.0001, as judged by the repeated-measure analysis of variance method). (c) Spontaneous rib fractures in male (squares) and female (circles) FTI- and vehicle-treated _Lmna_HG/+ mice at the time that they died. The FTI-treated mice had fewer fractures (P < 0.0001 for both males and females).
Similar articles
- Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria.
Yang SH, Chang SY, Andres DA, Spielmann HP, Young SG, Fong LG. Yang SH, et al. J Lipid Res. 2010 Feb;51(2):400-5. doi: 10.1194/jlr.M002808. Epub 2009 Oct 26. J Lipid Res. 2010. PMID: 19965595 Free PMC article. - Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin.
Yang SH, Chang SY, Ren S, Wang Y, Andres DA, Spielmann HP, Fong LG, Young SG. Yang SH, et al. Hum Mol Genet. 2011 Feb 1;20(3):436-44. doi: 10.1093/hmg/ddq490. Epub 2010 Nov 18. Hum Mol Genet. 2011. PMID: 21088111 Free PMC article. - A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation.
Yang SH, Meta M, Qiao X, Frost D, Bauch J, Coffinier C, Majumdar S, Bergo MO, Young SG, Fong LG. Yang SH, et al. J Clin Invest. 2006 Aug;116(8):2115-21. doi: 10.1172/JCI28968. J Clin Invest. 2006. PMID: 16862216 Free PMC article. - Targeting protein prenylation in progeria.
Young SG, Yang SH, Davies BS, Jung HJ, Fong LG. Young SG, et al. Sci Transl Med. 2013 Feb 6;5(171):171ps3. doi: 10.1126/scitranslmed.3005229. Sci Transl Med. 2013. PMID: 23390246 Free PMC article. Review. - Status of treatment strategies for Hutchinson-Gilford progeria syndrome with a focus on prelamin: A posttranslational modification.
Chen X, Yao H, Andrés V, Bergo MO, Kashif M. Chen X, et al. Basic Clin Pharmacol Toxicol. 2022 Oct;131(4):217-223. doi: 10.1111/bcpt.13770. Epub 2022 Jul 14. Basic Clin Pharmacol Toxicol. 2022. PMID: 35790078 Free PMC article. Review.
Cited by
- Modulation of LMNA splicing as a strategy to treat prelamin A diseases.
Lee JM, Nobumori C, Tu Y, Choi C, Yang SH, Jung HJ, Vickers TA, Rigo F, Bennett CF, Young SG, Fong LG. Lee JM, et al. J Clin Invest. 2016 Apr 1;126(4):1592-602. doi: 10.1172/JCI85908. Epub 2016 Mar 21. J Clin Invest. 2016. PMID: 26999604 Free PMC article. - Progeroid syndrome patients with ZMPSTE24 deficiency could benefit when treated with rapamycin and dimethylsulfoxide.
Akinci B, Sankella S, Gilpin C, Ozono K, Garg A, Agarwal AK. Akinci B, et al. Cold Spring Harb Mol Case Stud. 2017 Jan;3(1):a001339. doi: 10.1101/mcs.a001339. Cold Spring Harb Mol Case Stud. 2017. PMID: 28050601 Free PMC article. - Understanding the roles of nuclear A- and B-type lamins in brain development.
Young SG, Jung HJ, Coffinier C, Fong LG. Young SG, et al. J Biol Chem. 2012 May 11;287(20):16103-10. doi: 10.1074/jbc.R112.354407. Epub 2012 Mar 13. J Biol Chem. 2012. PMID: 22416132 Free PMC article. Review. - Inner nuclear membrane proteins: impact on human disease.
Méndez-López I, Worman HJ. Méndez-López I, et al. Chromosoma. 2012 Apr;121(2):153-67. doi: 10.1007/s00412-012-0360-2. Epub 2012 Feb 4. Chromosoma. 2012. PMID: 22307332 Review. - Epidermal expression of the truncated prelamin A causing Hutchinson-Gilford progeria syndrome: effects on keratinocytes, hair and skin.
Wang Y, Panteleyev AA, Owens DM, Djabali K, Stewart CL, Worman HJ. Wang Y, et al. Hum Mol Genet. 2008 Aug 1;17(15):2357-69. doi: 10.1093/hmg/ddn136. Epub 2008 Apr 28. Hum Mol Genet. 2008. PMID: 18442998 Free PMC article.
References
- Debusk FL. The Hutchinson-Gilford progeria syndrome. J. Pediatr. 1972;80:697–724. - PubMed
- Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, Dutra A, Pak E, Durkin S, Csoka AB, Boehnke M, Glover TW, Collins FS. Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome. Nature. 2003;423:293–298. - PMC - PubMed
- de Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, Lévy N. Lamin A truncation in Hutchinson–Gilford progeria. Science. 2003;300:2055. - PubMed
- Young SG, Fong LG, Michaelis S. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria—New evidence suggesting that protein farnesylation could be important for disease pathogenesis. J Lipid Res. 2005;46:2531–2558. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- R01 AR050200-02S1/AR/NIAMS NIH HHS/United States
- R01 AR050200-04/AR/NIAMS NIH HHS/United States
- R01 HL086683/HL/NHLBI NIH HHS/United States
- R01 AR050200-01/AR/NIAMS NIH HHS/United States
- R01 AR050200-06/AR/NIAMS NIH HHS/United States
- HL76839/HL/NHLBI NIH HHS/United States
- R01 HL076839/HL/NHLBI NIH HHS/United States
- R01 AR050200-03/AR/NIAMS NIH HHS/United States
- AR050200/AR/NIAMS NIH HHS/United States
- R01 HL076839-02/HL/NHLBI NIH HHS/United States
- R01 HL076839-01A1/HL/NHLBI NIH HHS/United States
- R01 AR050200/AR/NIAMS NIH HHS/United States
- R01 HL076839-03/HL/NHLBI NIH HHS/United States
- HL86683/HL/NHLBI NIH HHS/United States
- R01 AR050200-05/AR/NIAMS NIH HHS/United States
- R01 AR050200-02/AR/NIAMS NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous